ÎÚÑ»´«Ã½

Timely and Equitable Pain Management for Sickle Cell Disease in the Emergency Department

In partnership with a panel of clinical and patient experts, including emergency physicians, and the Health Services Advisory Group (HSAG), ASH has developed two facility-level electronic clinical quality measures (eCQMs) addressing timely and equitable pain management in the emergency department for individuals living with sickle cell disease:

1. Median Time to Pain Medication for Patients with a Diagnosis of Sickle Cell Disease (SCD) with Vaso-Occlusive Episode (VOE):
   Median time (in minutes) from Emergency Department (ED) arrival to initial administration of pain medication for all patients, regardless of age, with a principal encounter diagnosis of SCD with VOE
   
   This measure is under consideration for inclusion in CMS’ Hospital Outpatient Quality Reporting Program (HOQR) and the Rural Emergency Hospital Quality Reporting Program (REHQR). CMS will publish the measures under consideration (MUC) list by December 1, 2024. Once published, ASH will promote the opportunity to provide comments.
2. Difference in Median Times to Pain Medication Between Patients with a Diagnosis of Sickle Cell Disease (SCD) with Vaso-Occlusive Episode (VOE) and Renal Colic:
   Difference in median times from ED arrival to initial administration of pain medication between adult patients with a principal diagnosis of SCD with VOE and adult patients with a principal diagnosis of renal colic.

Improving Diagnosis of VTE in the Emergency Department

In partnership with a panel of clinical and patient experts, including emergency physicians, and the Health Services Advisory Group (HSAG), ASH has developed measures that aim to improve the diagnosis of venous thromboembolism (VTE) using Clinical Pretest Probability Tools. This effort was supported in part with funding from the Gordon and Betty Moore Foundation:

Previously Developed Measures

• MYELODYSPLASTIC SYNDROMES AND ACUTE LEUKEMIAS MEASURES - HEMATOLOGY MEASURE #1: MYELODYSPLASTIC SYNDROME (MDS) AND ACUTE LEUKEMIAS: BASELINE CYTOGENETIC TESTING PERFORMED ON BONE MARROW

• MYELODYSPLASTIC SYNDROMES MEASURE - HEMATOLOGY MEASURE #2: MYELODYSPLASTIC SYNDROME (MDS): DOCUMENTATION OF IRON STORES IN PATIENTS RECEIVING ERYTHROPOIETIN THERAPY

• MULTIPLE MYELOMA MEASURE - HEMATOLOGY MEASURE #3: MULTIPLE MYELOMA: TREATMENT WITH BISPHOSPHONATES

• CHRONIC LYMPHOCYTIC LEUKEMIA MEASURE - HEMATOLOGY MEASURE #4: CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): BASELINE FLOW CYTOMETRY

Externally Developed Quality Measures

The following externally developed measures may be of interest to practicing hematologists. Quality measures posted reflect those which were determined to be clinically relevant and valuable, feasible for use, and the result of a rigorous evaluation of evidence and development process. This listing as updated on February 13, 2023, and is provided as a reference only. ASH does not endorse externally developed measures.